Is Auna S.A. (AUNA) Stock Outpacing Its Medical Peers This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Auna S.A. (AUNA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Auna S.A. is one of 1012 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Auna S.A. is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for AUNA's full-year earnings has moved 8.3% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.According to our latest data, AUNA has moved about 25.8% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.9% on a year-to-date basis. As we can see, Auna S.A. is performing better than its sector in the calendar year.Another Medical stock, which has outperformed the sector so far this year, is BioMarin Pharmaceutical (BMRN). The stock has returned 8.3% year-to-date.In BioMarin Pharmaceutical's case, the consensus EPS estimate for the current year increased 10.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Auna S.A. belongs to the Medical Services industry, which includes 59 individual stocks and currently sits at #83 in the Zacks Industry Rank. On average, stocks in this group have gained 4.1% this year, meaning that AUNA is performing better in terms of year-to-date returns.BioMarin Pharmaceutical, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 510-stock industry is ranked #70. The industry has moved +7.1% so far this year.Auna S.A. and BioMarin Pharmaceutical could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Auna S.A. (AUNA): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks